FDA: Abbott failed to reveal facts about Prism

The FDA says product information sheets, a launch presentation and a customer letter for Abbott’s Prism HBsAg (antibody to hepatitis B surface antigen [mouse monoclonal IgM]) and Prism HBcore (hepatitis B virus core antigen [E. coli, [recombinant]) were false and misleading because they failed to reveal facts on important risks associated with the products.

You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory